ArticleOPEN ACCESS

Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021

European Heart Journal - Cardiovascular Pharmacotherapy
DOI: 10.1093/ehjcvp/pvab081
8Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Author supplied keywords

Cite

CITATION STYLE

APA

Mone, P., Trimarco, B., & Santulli, G. (2022, May 1). Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021. European Heart Journal - Cardiovascular Pharmacotherapy. Oxford University Press. https://doi.org/10.1093/ehjcvp/pvab081

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free